60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. The company was founded in 2010 and is headquartered in Washington, District Of Columbia. Show more
Location: 1025 Connecticut Avenue NW, Washington, DC, 20036, United States | Website: https://www.60degreespharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
2.578M
52 Wk Range
$1.41 - $36.00
Previous Close
$1.75
Open
$1.71
Volume
532,698
Day Range
$1.62 - $1.75
Enterprise Value
9.681M
Cash
3.452M
Avg Qtr Burn
-1.526M
Insider Ownership
4.97%
Institutional Own.
7.30%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Arakoda Details Malaria | Approved Quarterly sales | |
SJ733 Details Malaria | Phase 2b Initiation | |
Tafenoquine Details Babesiosis | Phase 2a Initiation | |
Tafenoquine Details COVID-19 | Failed Discontinued |